ARS Pharmaceuticals SPRY Cash Flow Statement (2020-2026)

NASDAQ SPRY
$5.62 -0.05 (-0.88%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

ARS Pharmaceuticals Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

ARS Pharmaceuticals reported cash from operations of -$60.93M and free cash flow of -$60.93M for the quarter ended Jun 2026, down 53.9% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-22.71M46.66M-7.10M-6.34M-6.63M-15.04M-19.05M-20.85M-17.96M-10.02M-13.37M-15.36M-21.26M47.08M-37.33M-47.73M-53.15M-41.33M-62.81M-63.99M
Share-based CompensationStock Comp.
9.56M-11.21M11.32M11.32M11.32M4.76M15.58M15.38M14.91M2.28M14.40M14.44M15.18M4.26M17.35M17.27M17.11M5.74M20.33M46.90M
Gains from Investment SecuritiesGains Investment
-0.00M-0.00M0.14M
Cash from OperationsCash from Ops.
-19.12M27.89M-6.92M-6.97M-5.68M-20.50M-12.43M-16.67M-12.76M-17.41M-6.71M-7.28M-14.47M42.00M-40.74M-39.59M-47.05M-43.48M-44.95M-60.93M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.34M0.24M0.28M-1.81M-1.75M-1.56M-1.73M-1.98M5.86M1.83M1.54M1.96M1.47M1.09M1.00M0.99M0.65M
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
0.21M0.10M0.01M0.02M0.10M0.03M0.28M0.28M0.39M0.42M0.40M0.42M
Change in Working Capital
Change in ReceivablesChange Receivables
0.77M7.40M1.13M13.25M14.01M-11.18M0.84M20.63M
Change in InventoryChange Inventory
0.18M5.76M8.45M4.78M-0.96M9.72M0.29M-0.01M
Change in Accured ExpensesChange Accured Exp.
-0.37M-5.45M0.55M-0.27M0.86M-11.42M4.76M0.22M1.12M-8.88M1.34M3.07M4.34M7.66M4.17M12.81M10.96M-9.06M10.31M10.52M
Other Working Capital ChangesOther WC Changes
-0.66M-0.46M-0.19M-3.13M-0.01M2.09M-0.21M-0.03M-0.06M-0.06M-0.06M-0.03M
Investing Activities
Capital ExpendituresCapex
0.09M-0.77M0.02M0.02M0.03M0.13M0.19M0.03M0.04M-0.09M0.08M0.04M0.14M0.30M0.09M0.05M0.20M
Change in Acquisitions & DivestmentsChange Acquisitions
20.00M45.00M60.00M60.00M55.00M75.00M61.00M67.00M63.50M80.00M88.50M75.00M42.50M61.48M
Cash from Investing ActivitiesCash from Investing
-40.06M40.74M-0.02M-0.02M-0.03M-0.13M-111.55M44.97M-46.64M26.04M-8.51M-12.65M16.82M-101.76M29.06M48.57M-44.98M24.11M27.79M41.57M
Financing Activities
Other financing activitiesOther financing
0.15M-1.02M0.29M0.28M1.32M2.85M0.92M1.80M0.26M0.55M0.68M1.53M0.72M2.70M0.48M1.78M0.06M0.79M
Cash from Financing ActivitiesCash from Financing
0.15M52.82M-0.91M-0.62M-1.56M193.82M1.32M2.85M0.92M1.80M0.26M0.55M0.68M70.92M0.72M2.70M100.05M1.13M0.16M3.20M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.51M1.83M1.47M4.10M4.75M3.07M5.32M2.64M3.36M3.70M
Net Equity Issued and RepurchasedNet Equity Issued
54.81M
Additional items
Change in Cash
-59.03M121.45M-7.85M-7.62M-7.27M173.20M-122.66M31.16M-58.48M10.44M-14.96M-19.38M3.03M11.16M-10.95M11.68M8.02M-18.24M-17.00M-16.16M
Free Cash FlowFCF
-19.21M28.66M-6.95M-7.00M-5.71M-20.62M-12.62M-16.70M-12.81M-17.31M-6.79M-7.32M-14.61M41.70M-40.83M-39.64M-47.24M-43.48M-44.95M-60.93M
Net Cash FlowNCF
-59.03M121.45M-7.85M-7.62M-7.27M173.20M-122.66M31.16M-58.48M10.44M-14.96M-19.38M3.03M11.16M-10.95M11.68M8.02M-18.24M-17.00M-16.16M